Latest News

Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • March 06, 2019 8:41 AM | Deleted user

    March 6, 2019, JAAPA 

    Women with opioid use disorder who become pregnant are a particularly vulnerable population and require a comprehensive treatment approach for mother and fetus. Research is continuing on opioid use disorder, effects of opioid use on the fetus, and best treatment approaches. This article reviews current recommendations and guidelines for treatment.

    Read more.

  • March 05, 2019 8:31 AM | Deleted user

    March 5, 2019, MedPage Today 

    Most cases of cervical cancer worldwide could be eliminated at the end of this century if the human papilloma virus (HPV) vaccination and screening efforts are rapidly expanded, researchers suggest.

    Read more

  • March 05, 2019 8:22 AM | Deleted user

    March 5, 2019, HemOnc Today 

    Cryoablation may be an effective primary treatment option for women with low-risk breast cancer, according to preliminary findings from the Ice 3 trial. The trial included women aged 60 years and older who underwent cryoablation across 20 centers in the U.S. for low-risk breast cancer. Researchers will use mammography to monitor the women for breast cancer recurrence at 6 months and 12 months, and then annually for 5 years. 

    Read more.

  • March 04, 2019 9:22 AM | Deleted user

    March 4, 2019, MedPage Today 

    WASHINGTON -- Injectable collagenase clostridium histolyticum (CCH) was an effective treatment option for women with cellulite on the buttocks, according to researchers here.

    Based on results from two randomized, double-blind, placebo-controlled, phase III trials (Release-1 and Release-2), CCH (Xiaflex) significantly improved cellulite severity in women with moderate to severe cellulite on the buttocks, reported Joely Kaufman, MD, of the Skin Associates of South Florida in Coral Gables, and colleagues, at the American Academy of Dermatology meeting.

    Read more.

  • March 04, 2019 9:19 AM | Deleted user

    March 4, 2019, MedPage Today OB/GYN Update 

    Pregnancies shortly after a stillbirth were not linked with an increased risk of adverse outcomes compared to those where women waited longer to conceive, researchers found.

    In a study of over 14,000 women who had a stillbirth, pregnancy intervals ≤12 months were not associated with a higher risk of subsequent stillbirth, preterm birth, or small-for-gestational-age birth compared with intervals of 24-59 months following a stillbirth, reported Annette Regan, PhD, of Curtin University in Perth, Australia, and colleagues in The Lancet.

    Read more.
  • March 04, 2019 9:13 AM | Deleted user

    March 4, 2019, MedPage Today  

    Women with advanced ovarian cancer and clinically negative lymph nodes at surgery did not live longer if they underwent pelvic and paraaortic lymphadenectomy, final results of a randomized trial showed. 

    Read more.

  • March 01, 2019 8:41 AM | Deleted user

    March 1, 2019, MedPage Today 

    The identification of biomarkers to cluster breast cancer patients into subgroups based on their immune evasion mechanisms may help guide the choice of immunotherapy, according to new research. The findings provide a better understanding of the response to immunotherapies and shed light on the rational design of novel combination therapies, the team said. 

    Read more.

  • March 01, 2019 8:39 AM | Deleted user

    March 1, 2019, Cardiology Today 

    BMI increased more and total cholesterol decreased less in women compared with men during a 15-year period, according to an analysis of temporal trends in CV risk factor levels. The researchers assessed sex differences in temporal trends for risk factors, including systolic BP, BMI, smoking status, and HDL and total cholesterol. Trends in treatment and control rates of hypertension, diabetes, and dyslipidemia were also analyzed. 

    Read more.

  • March 01, 2019 8:38 AM | Deleted user

    March 1, 2019, HealthDay News via Monthly Prescribing Reference 

    The battle against new HIV infections has lost some steam in recent years, according to the U.S. Centers for Disease Control and Prevention. After about five years of significant declines, the number of new HIV infections began to level off in 2013, at about 39,000 infections per year. The reason for the slowing, according to the CDC, is that effective HIV prevention and treatments are not reaching those who could most benefit. These shortfalls in prevention and treatment are most glaring in rural areas and in the South, and they disproportionately affect blacks and Hispanics. 

    Read more.

  • March 01, 2019 8:36 AM | Deleted user

    March 1, 2019, HemOnc Today 

    Sacituzumab govitecan induced durable responses in patients with heavily pretreated metastatic triple-negative breast cancer, according to results of a phase 1/2 single-group trial published in The New England Journal of Medicine. The antibody-drug conjugate also appeared safe among these patients, who achieved better outcomes than those associated with standard chemotherapy for triple-negative disease. 

    Read more.

Powered by Wild Apricot Membership Software